Role of Nuclear Transcription Factor Nrf2 in Parkinson’s Disease

doi:10.3969/j.issn.2095-1396.2016.01.005

Abstract

Abstract: Nuclear factor erythroid-2-realted factor 2 （Nrf2） is an important transcription factor for cells to mediate the resistance to oxidative stress. As a pivotal protective mechanism，it binds to antioxidant response element （ARE） to resist internal and external oxidative stress.Recent studies have shown that the Keap1-Nrf2-ARE signaling pathway plays an important neuroprotective role in patients with Parkinson’s disease. In this paper，the role and its underlying mechanisms of Nrf2 in the treatment of Parkinson’s disease（PD），as well as the latest research achievements targeting Nrf2 for PD are summarized.

Key words: nuclear factor erythroid-2-related factor 2（Nrf2）, Parkinson&, rsquo, s disease（PD）, oxidative stress

CLC Number:

R965

ZHANG Mei-jin，WANG Sha-sha，ZHANG Zhao，CHEN Nai-hong，HU Jin-feng. Role of Nuclear Transcription Factor Nrf2 in Parkinson’s Disease[J]. Acta Neuropharmacologica, 2016, 6(1): 35-40.

References

[1] David T Dexter, Peter Jenner. Parkinson disease: from pathology to molecular disease mechanisms[J]Free Radical Biology & Medicine, 2013, 62: 132-144.

[2] Denis Ottolini, Tito Cali, Alessandro Negro, et al. The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering[J].Human Molecular Genetics, 2013, 22(11): 2152-2168.

[3] Hans-Hermann Hoepken, Suzana Gispert, Mekhman Azizov, et al. Parkinson patient fibroblasts show increased alpha-synuclein expression[J].Experimental Neurology, 2008, 212(2): 307-313.

[4] Filio Billia, Ludger Hauck, Daniela Grothe, et al. Parkinson-susceptibility gene DJ-1/PARK7 protects the murine heart from oxidative damage in vivo[J].Proceedings National Academy Sciences USA, 2013, 110(15): 6085-6090.

[5] Antonio Cuadrado, Paz Moreno-Murciano, Jose Pedraza-Chaverri. The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease[J].Expert Opinion Therapeutic Targets, 2009, 13(3): 319-329.

[6] Moi P, Chan K, Asunis I, et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region[J]. Proceedings National Academy Sciences USA, 1994, 91(21): 9926-9930.

[7] Yu Xiang, Thomas Kensler. Nrf2 as a target for cancer chemoprevention[J]. Mutation Res, 2005, 591(1-2):93-102.

[8] Lv E, Deng J, Yu Y, et al. Nrf2-ARE signals mediated the anti-oxidative action of electroacupuncture in an MPTP mouse model of Parkinson's disease[J]. Free Radical Res, 2015, 49(11): 1296-1307.

[9] Gerasimos P Sykiotis, Dirk Bohmann. Stress-activated cap'n'collar transcription factors in aging and human disease[J]. Science Signaling, 2010, 3(112): re3.

[10] Yaeko Takagi, Makoto Kobayashi, Li Li, et al. MafT, a new member of the small Maf protein family in zebrafish[J]. Biochemical Biophysical Research Communications, 2004, 320(1): 62-69.

[11] Wang Bing, Liu Qing-qing, Shan Hong-yun, et al. Nrf2 inducer and cncC overexpression attenuates neurodegeneration due to alpha-synuclein in Drosophila[J]. Biochemistry Cell Biology, 2015, 93(4): 351-358.

[12] Gui Ya-xing, Zhang Li-shan, Lv Wen, et al. NFE2L2 variations reduce antioxidant response in patients with Parkinson disease[J]. Oncotarget, 2016, 7(10): 10756-10764.

[13] Marcelo R Vargas, Jeffrey A Johnson. The Nrf2-ARE cytoprotective pathway in astrocytes[J]. Expert Reviews Molecular Medicine, 2009, 11: e17.

[14] Jamie Gonzalez, Nicolas Valls, Roberto Brito, et al. Essential hypertension and oxidative stress: New insights[J]. J World Cardiology, 2014, 6(6): 353-366.

[15] Patricia M Chege, Gawain McColl. Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease[J]. Frontiers Aging Neuroscience, 2014, 6: 89.

[16] Justin Davis, Steven Moylan, Brian H Harvey, et al. Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries[J]. J Australian New Zealand Psychiatry, 2014, 48(6): 512-529.

[17] Helga E de Vries, Maarten Witte, David Hondius, et al. Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?[J].Free Radical Biology & Medicine, 2008, 45(10): 1375-1383.

[18] Gururaj Joshi, Jeffrey A Johnson. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases[J]. Recent Patents CNS Drug Discovery, 2012, 7(3):218-229.

[19] Jong-Min Lee, Andy Y Shih, Timothy H Murphy, et al. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons[J]. J Biological Chemistry, 2003, 278(39): 37948-37956.

[20] Izaskun Buendia, Patrycja Michalska, Elisa Navarro, et al. Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases[J]. Pharmacology & Therapeutics, 2016, 157: 84-104.

[21] Sankar Surendran, Srinivasagam Raja Sankar. Parkinson's disease: oxidative stress and therapeutic approaches[J]. Neurol Sci, 2010, 31(5): 531-540.

[22] Chenere P Ramsey, Charles A Glass, Marshall B Montgomery, et al. Expression of Nrf2 in neurodegenerative diseases[J]. J Neuropathol Exp Neurol, 2007, 66(1): 75-85.

[23] Ali Samii, John Nutt, Bruce R Ransom. Parkinson's disease[J]. Lancet, 2004, 363(9423): 1783-1793.

[24] Suzanne Lesage, Alexis Brice. Parkinson's disease: from monogenic forms to genetic susceptibility factors[J]. Human Molecular Gen, 2009, 18(R1): R48-59.

[25] John N Caviness, LihFen Lue, Charles H Adler, et al. Parkinson's disease dementia and potential therapeutic strategies[J]. CNS Neuroscience & Therapeutics, 2011, 17(1): 32-44.

[26] Radhika Sampat, Sarah Young, Ami Rosen, et al. Potential mechanisms for low uric acid in Parkinson disease[J]. J Neural Transm, 2016, 123(4): 365-370.

[27] Delinda A Johnson, Jeffrey A Johnson. Nrf2-a therapeutic target for the treatment of neurodegenerative diseases[J]. Free Radical Biology & Medicine, 2015, 88(Pt B): 253-267.

[28] Brent J Ryan, Lara L Lourenco-Venda, Mark J Crabtree, et al. alpha-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease[J]. Free Radical Biology & Medicine, 2014, 67: 58-68.

[29] Gan Li, Jeffrey A Johnson. Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases[J]. Biochimica et Biophysica Acta, 2014, 1842(8): 1208-1218.

[30] He Qing, Song Ning, Jia Feng-jv, et al. Role of alpha-synuclein aggregation and the nuclear factor E2-related factor 2/heme oxygenase-1 pathway in iron-induced neurotoxicity[J]. J Int Biochemistry & Cell Biology, 2013, 45(6): 1019-1030.

[31] Li Gan, Marcelo R Vargas, Delinda A Johnson, et al. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model[J]. J Neuroscience, 2012, 32(49): 17775-17787.

[32] Lin Xiang-min, Travis J Cook, Cyrus P Zabetian, et al. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease[J]. Scientific Reports, 2012, 2(50): 954.

[33] Casey M Clements, Richard S McNally, Brian J Conti, et al. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2[J]. Proceedings National Academy of Sciences USA, 2006, 103(41): 15091-15096.

[34] Zhou Wen-bo, Curt R Freed. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity[J]. J Biological Chemistry, 2005, 280(52): 43150-43158.

[35] Ana I Rojo, Nadia G Innamorato, Ana M Martin-Moreno, et al. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease[J].Glia, 2010, 58(5): 588-598.

[36] Rebekah J Jakel, Jessica A Townsend, Andrew D Kraft, et al. Nrf2-mediated protection against 6-hydroxydopamine[J]. Brain Res, 2007, 1144: 192-201.

[37] Agnieszka Jazwa, Ana I Rojo, Nadia G Innamorato, et al. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism[J].Antioxidants & Redox Signaling, 2011, 14(12): 2347-2360.

[38] Wruck C J, Claussen M, Fuhrmann G, et al. Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway[J]. J Neural Transm Suppl, 2007, (72): 57-67.

[39] Zhao Chun-yang, Wang Xiao-liang, Peng Ying. [Role of Nrf2 in neurodegenerative diseases and recent progress of its activators][J]. Acta Pharmaceutica Sinica, 2015, 50(4): 375-384.

[40] Susanne Petri, Sonja Korner, Mahmoud Kiaei. Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS[J].Neurology Res Int, 2012, 2012: 878030.

[41] Tracy P Williamson, Delinda A Johnson, Jeffrey A Johnson. Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity[J].Neurotoxicology, 2012, 33(3): 272-279.

[42] Chen Pei-chun, Marcelo R Vargas, Amar K Pani, et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte[J].Proceed National Academy of Sciences USA, 2009, 106(8): 2933-2938.

[43] Hyman M Schipper. Heme oxygenase expression in human central nervous system disorders[J].Free Radical Biology Med, 2004, 37(12):1995-2011.

[44] Andy Y Shih, Delinda A Johnson, Gloria Wong, et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress[J]. J Neuroscience, 2003, 23(8):3394-3406.

[45] Xiao Hai-bing, Lv Feng, Xu Wu-ping, et al. Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk[J].Toxicology, 2011, 290(2-3): 286-294.